Published in Ann Transl Med on February 01, 2015
Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget (2015) 0.81
Erratum: Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research: Erratum. Ann Transl Med (2015) 0.75
Long non-coding RNAs in cutaneous melanoma: clinical perspectives. Oncotarget (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Mitogen-activated protein kinase pathways. Curr Opin Cell Biol (1997) 9.10
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res (2006) 3.32
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature (2014) 2.84
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell (2014) 2.40
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene (2010) 1.57
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol (2014) 1.47
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol (2012) 1.18
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther (2013) 1.13
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab (2015) 1.08
Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. Oncol Lett (2014) 0.95
Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol (2013) 0.89
Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother (2014) 0.89
Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer (2014) 0.88
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85
Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother (2014) 0.81